1152 related articles for article (PubMed ID: 32075939)
21. A Kunjin Replicon Virus-like Particle Vaccine Provides Protection Against Ebola Virus Infection in Nonhuman Primates.
Pyankov OV; Bodnev SA; Pyankova OG; Solodkyi VV; Pyankov SA; Setoh YX; Volchkova VA; Suhrbier A; Volchkov VV; Agafonov AA; Khromykh AA
J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S368-71. PubMed ID: 25732811
[TBL] [Abstract][Full Text] [Related]
22. First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered in different sequences and schedules: A randomized, controlled study.
Bockstal V; Shukarev G; McLean C; Goldstein N; Bart S; Gaddah A; Anumenden D; Stoop JN; Marit de Groot A; Pau MG; Hendriks J; De Rosa SC; Cohen KW; McElrath MJ; Callendret B; Luhn K; Douoguih M; Robinson C
PLoS One; 2022; 17(10):e0274906. PubMed ID: 36197845
[TBL] [Abstract][Full Text] [Related]
23. Human Polyclonal Antibodies Produced through DNA Vaccination of Transchromosomal Cattle Provide Mice with Post-Exposure Protection against Lethal Zaire and Sudan Ebolaviruses.
Bounds CE; Kwilas SA; Kuehne AI; Brannan JM; Bakken RR; Dye JM; Hooper JW; Dupuy LC; Ellefsen B; Hannaman D; Wu H; Jiao JA; Sullivan EJ; Schmaljohn CS
PLoS One; 2015; 10(9):e0137786. PubMed ID: 26422247
[TBL] [Abstract][Full Text] [Related]
24. Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates.
Marzi A; Engelmann F; Feldmann F; Haberthur K; Shupert WL; Brining D; Scott DP; Geisbert TW; Kawaoka Y; Katze MG; Feldmann H; Messaoudi I
Proc Natl Acad Sci U S A; 2013 Jan; 110(5):1893-8. PubMed ID: 23319647
[TBL] [Abstract][Full Text] [Related]
25. Ebolavirus Glycoprotein Fc Fusion Protein Protects Guinea Pigs against Lethal Challenge.
Konduru K; Shurtleff AC; Bradfute SB; Nakamura S; Bavari S; Kaplan G
PLoS One; 2016; 11(9):e0162446. PubMed ID: 27622456
[TBL] [Abstract][Full Text] [Related]
26. A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA.
Ewer K; Rampling T; Venkatraman N; Bowyer G; Wright D; Lambe T; Imoukhuede EB; Payne R; Fehling SK; Strecker T; Biedenkopf N; Krähling V; Tully CM; Edwards NJ; Bentley EM; Samuel D; Labbé G; Jin J; Gibani M; Minhinnick A; Wilkie M; Poulton I; Lella N; Roberts R; Hartnell F; Bliss C; Sierra-Davidson K; Powlson J; Berrie E; Tedder R; Roman F; De Ryck I; Nicosia A; Sullivan NJ; Stanley DA; Mbaya OT; Ledgerwood JE; Schwartz RM; Siani L; Colloca S; Folgori A; Di Marco S; Cortese R; Wright E; Becker S; Graham BS; Koup RA; Levine MM; Volkmann A; Chaplin P; Pollard AJ; Draper SJ; Ballou WR; Lawrie A; Gilbert SC; Hill AV
N Engl J Med; 2016 Apr; 374(17):1635-46. PubMed ID: 25629663
[TBL] [Abstract][Full Text] [Related]
27. Cross-protection conferred by filovirus virus-like particles containing trimeric hybrid glycoprotein.
Martins K; Carra JH; Cooper CL; Kwilas SA; Robinson CG; Shurtleff AC; Schokman RD; Kuehl KA; Wells JB; Steffens JT; van Tongeren SA; Hooper JW; Bavari S
Viral Immunol; 2015 Feb; 28(1):62-70. PubMed ID: 25514232
[TBL] [Abstract][Full Text] [Related]
28. Venezuelan equine encephalitis virus replicon particle vaccine protects nonhuman primates from intramuscular and aerosol challenge with ebolavirus.
Herbert AS; Kuehne AI; Barth JF; Ortiz RA; Nichols DK; Zak SE; Stonier SW; Muhammad MA; Bakken RR; Prugar LI; Olinger GG; Groebner JL; Lee JS; Pratt WD; Custer M; Kamrud KI; Smith JF; Hart MK; Dye JM
J Virol; 2013 May; 87(9):4952-64. PubMed ID: 23408633
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of Vesicular Stomatitis Virus-Ebola Virus Postexposure Treatment in Rhesus Macaques Infected With Ebola Virus Makona.
Marzi A; Hanley PW; Haddock E; Martellaro C; Kobinger G; Feldmann H
J Infect Dis; 2016 Oct; 214(suppl 3):S360-S366. PubMed ID: 27496978
[TBL] [Abstract][Full Text] [Related]
30. T-cell-dependent mechanisms promote Ebola VLP-induced antibody responses, but are dispensable for vaccine-mediated protection.
Cooper CL; Martins KA; Stronsky SM; Langan DP; Steffens J; Van Tongeren S; Bavari S
Emerg Microbes Infect; 2017 Jun; 6(6):e46. PubMed ID: 28588288
[TBL] [Abstract][Full Text] [Related]
31. Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus.
Mire CE; Matassov D; Geisbert JB; Latham TE; Agans KN; Xu R; Ota-Setlik A; Egan MA; Fenton KA; Clarke DK; Eldridge JH; Geisbert TW
Nature; 2015 Apr; 520(7549):688-691. PubMed ID: 25853476
[TBL] [Abstract][Full Text] [Related]
32. Adjuvant-enhanced CD4 T Cell Responses are Critical to Durable Vaccine Immunity.
Martins KAO; Cooper CL; Stronsky SM; Norris SLW; Kwilas SA; Steffens JT; Benko JG; van Tongeren SA; Bavari S
EBioMedicine; 2016 Jan; 3():67-78. PubMed ID: 26870818
[TBL] [Abstract][Full Text] [Related]
33. A novel Ebola virus antibody-dependent cell-mediated cytotoxicity (Ebola ADCC) assay.
Singh K; Marasini B; Chen X; Spearman P
J Immunol Methods; 2018 Sep; 460():10-16. PubMed ID: 29894746
[TBL] [Abstract][Full Text] [Related]
34. Aerosolized Ebola vaccine protects primates and elicits lung-resident T cell responses.
Meyer M; Garron T; Lubaki NM; Mire CE; Fenton KA; Klages C; Olinger GG; Geisbert TW; Collins PL; Bukreyev A
J Clin Invest; 2015 Aug; 125(8):3241-55. PubMed ID: 26168222
[TBL] [Abstract][Full Text] [Related]
35. Macaque Monoclonal Antibodies Targeting Novel Conserved Epitopes within Filovirus Glycoprotein.
Keck ZY; Enterlein SG; Howell KA; Vu H; Shulenin S; Warfield KL; Froude JW; Araghi N; Douglas R; Biggins J; Lear-Rooney CM; Wirchnianski AS; Lau P; Wang Y; Herbert AS; Dye JM; Glass PJ; Holtsberg FW; Foung SK; Aman MJ
J Virol; 2016 Jan; 90(1):279-91. PubMed ID: 26468532
[TBL] [Abstract][Full Text] [Related]
36. Preclinical Development of Inactivated Rabies Virus-Based Polyvalent Vaccine Against Rabies and Filoviruses.
Willet M; Kurup D; Papaneri A; Wirblich C; Hooper JW; Kwilas SA; Keshwara R; Hudacek A; Beilfuss S; Rudolph G; Pommerening E; Vos A; Neubert A; Jahrling P; Blaney JE; Johnson RF; Schnell MJ
J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S414-24. PubMed ID: 26063224
[TBL] [Abstract][Full Text] [Related]
37. Respiratory tract immunization of non-human primates with a Newcastle disease virus-vectored vaccine candidate against Ebola virus elicits a neutralizing antibody response.
DiNapoli JM; Yang L; Samal SK; Murphy BR; Collins PL; Bukreyev A
Vaccine; 2010 Dec; 29(1):17-25. PubMed ID: 21034822
[TBL] [Abstract][Full Text] [Related]
38. Species-specific immunogenicity and protective efficacy of a vesicular stomatitis virus-based Sudan virus vaccine: a challenge study in macaques.
Marzi A; Fletcher P; Feldmann F; Saturday G; Hanley PW; Feldmann H
Lancet Microbe; 2023 Mar; 4(3):e171-e178. PubMed ID: 36739878
[TBL] [Abstract][Full Text] [Related]
39. Correlates of vaccine-induced protective immunity against Ebola virus disease.
Medaglini D; Santoro F; Siegrist CA
Semin Immunol; 2018 Oct; 39():65-72. PubMed ID: 30041831
[TBL] [Abstract][Full Text] [Related]
40. Antiviral Innate Responses Induced by VSV-EBOV Vaccination Contribute to Rapid Protection.
Menicucci AR; Jankeel A; Feldmann H; Marzi A; Messaoudi I
mBio; 2019 May; 10(3):. PubMed ID: 31138743
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
